NCT02909348View on ClinicalTrials.gov

Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
NeoplasmsMelanoma
Interventions
DRUG

Pembrolizumab

3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.

Trial Locations (2)

TR1 3LQ

The Royal Cornwall Hospital, Treliske

NW3 2QG

Royal Free London NHS Foundation Trust, London

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

University College, London

OTHER

lead

Royal Free Hospital NHS Foundation Trust

OTHER